LY6G6E

Across TCGA pan-cancer cohorts, LY6G6E Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LY6G6E data layer compared with 19 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher LY6G6E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LY6G6E expression acts as an unfavorable survival marker.

ESCA are the cancer types where LY6G6E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.222	0.680	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

LY6G6E–ESCA (OS)

Open the ESCA breakdown →